Bispecific antibody · Immune activation, directed at EpCAM and 4-1BB (CD137) (TNFRSF9) · developed by BioNTech
BNT314 is a bispecific antibody that binds EpCAM on tumor cells and the costimulatory receptor 4-1BB on leukocytes, including activated T lymphocytes. By crosslinking these cells, it activates 4-1BB signaling locally in the tumor microenvironment to co-stimulate cytotoxic T cells. It is studied in advanced malignant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06150183 | Phase 1 | Advanced Malignant Solid Tumor | Active not recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Malignant Solid Tumor
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →